SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: the eagle who wrote (670)2/15/1998 9:50:00 PM
From: David Cathcart  Read Replies (1) of 1826
 
The CEO Charles Blitzer came from Marion Labs and had a great track record there in making product acquisition and cross licensing deals. That's why I take him at his word when he says that the European deal for a MGI 114 partner will happen. Interestingly enough, the European deal is about the only thing he will commit to; he is very conservative when it comes to any type of financial or sales projections. Those who really know Blitzer's background will not be surprised whenever a major deal is announced, be it two weeks or two months from now, be it a European partner for MGI 114 or something entirely different. I can't say that I know anything about the rumor you speak of, but I do sense that 1998 will be the year that those who hold MOGN stock will be rewarded.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News